ALBT vs. MIRA, NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, and QTTB
Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.
Avalon GloboCare vs. Its Competitors
Avalon GloboCare (NASDAQ:ALBT) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 37.3% of Avalon GloboCare shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MIRA Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.
MIRA Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 743.37%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe MIRA Pharmaceuticals is more favorable than Avalon GloboCare.
MIRA Pharmaceuticals has lower revenue, but higher earnings than Avalon GloboCare. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
Avalon GloboCare has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
In the previous week, Avalon GloboCare had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 6 mentions for Avalon GloboCare and 4 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.92 beat Avalon GloboCare's score of 0.82 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.
Summary
MIRA Pharmaceuticals beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks.
Get Avalon GloboCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalon GloboCare Competitors List
Related Companies and Tools
This page (NASDAQ:ALBT) was last updated on 7/16/2025 by MarketBeat.com Staff
Free ALBT Stock Alerts